BiotechTube

JBT-101 + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatomyositis

Conditions

Dermatomyositis

Trial Timeline

Jun 1, 2015 → Jan 29, 2021

NCT ID
NCT02466243

About JBT-101 + Placebo

JBT-101 + Placebo is a phase 2 stage product being developed by Corbus Pharmaceuticals for Dermatomyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02466243. Target conditions include Dermatomyositis.

What happened to similar drugs?

0 of 3 similar drugs in Dermatomyositis were approved

Approved (0) Terminated (1) Active (2)
🔄DazukibartPfizerPhase 3
❌human immunoglobulin G + PlaceboCSLPhase 3
🔄Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03093402Phase 2Completed
NCT02466243Phase 2Terminated

Competing Products

14 competing products in Dermatomyositis

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
26
M5049 high dose + PlaceboMerckPhase 2
27
BAF312 + PlaceboNovartisPhase 2
27
MEDI7734 + PlaceboAmgenPhase 1
29
Etanercept + PlaceboAmgenPhase 1
29
DazukibartPfizerPhase 3
47
Anti-Beta Interferon (PF-06823859)PfizerPhase 2
35
PF-06823859 low + Placebo Arm + PF-06823859 highPfizerPhase 2
35
TofacitinibPfizerPhase 1
29
EmapalumabSwedish Orphan BiovitrumPhase 2
42
human immunoglobulin G + PlaceboCSLPhase 3
32
Empasiprubart IVArgenxPhase 2
36
GLPG3667 + PlaceboGalapagosPhase 2
33
Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3
30